case_images: PMC10105325_01
case_images: Pathology of patient case 1.
case_images: cro529315_f01.jpg
case_images: PMC10105325_01_cro529315_f01.jpg
case_images: F1
case_images: Histological examination of a brain biopsy confirmed the diagnosis of DLBCL (shown in Fig. 1).
case_images: MRI scans of the brain for patient one. a indicates the centrum semiovale and paraventricular violated at diagnosis. b shows tumor disappearing after one induction and two consolidation treatment based on MTX. c illustrates constant tumor negative after receiving zanubrutinib for 9 months.
case_images: cro529315_f02.jpg
case_images: PMC10105325_01_cro529315_f02.jpg
case_images: F2
case_images: So far, the man stays alive (shown in Fig. 2).
case_images: PMC10105325_02
case_images: Pathology of patient case 2.
case_images: cro529315_f03.jpg
case_images: PMC10105325_02_cro529315_f03.jpg
case_images: F3
case_images: Histology and IHC analysis revealed a DLBCL (shown in Fig. 3) with CD20, CD79a, MUM1 positive, Ki-67 positivity (approximately 60%), and BCL-6, CD21, and CD10 negative.
case_images: MRI scans of the brain for patient two. a indicates the right frontal cortex was violated at diagnosis. b shows tumor melting after one induction treatment. c illustrates cancer minimizing with 4 months of zanubrutinib treatment.
case_images: cro529315_f04.jpg
case_images: PMC10105325_02_cro529315_f04.jpg
case_images: F4
case_images: Three months after treatment, an MRI estimated that the tumor had shrunk and the patient could walk independently (shown in Fig. 4).